Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 294
6
Diseases
9
Unique genes
0.240
Avg. similarity score
Bronchus cancer
Most-connected disease (5 links)
Disease
Searched: dyskeratosis congenita, autosomal dominant 2
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
dyskeratosis congenita, autosomal dominant 2
Bronchus cancer
Respiratory system cancer
Cri-du-chat syndrome
Large cell carcinoma
Coumarin resistance
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Bronchus cancer | 5 | 5 | 5 |
| Respiratory system cancer | 4 | 4 | 5 |
| Cri-du-chat syndrome | 3 | 3 | 2 |
| Large cell carcinoma | 3 | 3 | 2 |
| dyskeratosis congenita, autosomal dominant 2 | 3 | 3 | 1 |
| Coumarin resistance | 2 | 2 | 3 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| CYP2A6 | 4 / 6 | Bronchus cancer, Coumarin resistance, Large cell carcinoma, Respiratory system cancer |
| TERT | 4 / 6 | Bronchus cancer, Cri-du-chat syndrome, dyskeratosis congenita, autosomal dominant 2, Respiratory system cancer |
| BRCA2 | 2 / 6 | Bronchus cancer, Respiratory system cancer |
| CHRNA4 | 2 / 6 | Bronchus cancer, Respiratory system cancer |
| CHRNA5 | 2 / 6 | Bronchus cancer, Respiratory system cancer |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Highly calcium permeable nicotinic acetylcholine receptors | Reactome | 2 / 9 | 297× | 1.79e-5 | 5.74e-4 ✓ sig. |
| CYP2E1 reactions | Reactome | 2 / 11 | 243× | 2.74e-5 | 8.18e-4 ✓ sig. |
| Highly calcium permeable postsynaptic nicotinic acetylcholine receptors | Reactome | 2 / 12 | 222× | 3.28e-5 | 9.46e-4 ✓ sig. |
| Xenobiotics | Reactome | 2 / 24 | 111× | 1.37e-4 | 2.97e-3 ✓ sig. |
| Lipid and atherosclerosis | KEGG | 3 / 216 | 18.5× | 4.45e-4 | 7.57e-3 ✓ sig. |
| Retinol metabolism | KEGG | 2 / 68 | 39.2× | 1.11e-3 | 1.52e-2 ✓ sig. |
| Chemical carcinogenesis - DNA adducts | KEGG | 2 / 70 | 38.1× | 1.17e-3 | 1.59e-2 ✓ sig. |
| Drug metabolism - cytochrome P450 | KEGG | 2 / 73 | 36.6× | 1.28e-3 | 1.69e-2 ✓ sig. |
| Metabolism of xenobiotics by cytochrome P450 | KEGG | 2 / 79 | 33.8× | 1.49e-3 | 1.91e-2 ✓ sig. |
| Metabolism of vitamin K | Reactome | 1 / 3 | 445× | 2.25e-3 | 2.58e-2 ✓ sig. |
| Caffeine metabolism | KEGG | 1 / 6 | 222× | 4.49e-3 | 4.21e-2 ✓ sig. |
| CLEC7A/inflammasome pathway | Reactome | 1 / 6 | 222× | 4.49e-3 | 4.21e-2 ✓ sig. |
| Biosynthesis of maresin-like SPMs | Reactome | 1 / 6 | 222× | 4.49e-3 | 4.21e-2 ✓ sig. |
| Highly sodium permeable postsynaptic acetylcholine nicotinic receptors | Reactome | 1 / 7 | 191× | 5.24e-3 | 4.67e-2 ✓ sig. |
| Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET) | Reactome | 1 / 8 | 167× | 5.98e-3 | 5.11e-2 |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| establishment of protein localization to telomere | GO:0070200 | 2 / 7 | 593× | 4.32e-6 | 2.75e-4 ✓ sig. |
| behavioral response to nicotine | GO:0035095 | 2 / 9 | 461× | 7.41e-6 | 4.26e-4 ✓ sig. |
| icosanoid biosynthetic process | GO:0046456 | 2 / 10 | 415× | 9.26e-6 | 5.10e-4 ✓ sig. |
| telomere maintenance via recombination | GO:0000722 | 2 / 11 | 378× | 1.13e-5 | 5.95e-4 ✓ sig. |
| xenobiotic metabolic process | GO:0006805 | 3 / 120 | 51.9× | 2.11e-5 | 9.67e-4 ✓ sig. |
| epoxygenase P450 pathway | GO:0019373 | 2 / 18 | 231× | 3.14e-5 | 1.31e-3 ✓ sig. |
| synaptic transmission, cholinergic | GO:0007271 | 2 / 25 | 166× | 6.15e-5 | 2.17e-3 ✓ sig. |
| acetylcholine receptor signaling pathway | GO:0095500 | 2 / 28 | 148× | 7.74e-5 | 2.59e-3 ✓ sig. |
| xenobiotic catabolic process | GO:0042178 | 2 / 28 | 148× | 7.74e-5 | 2.59e-3 ✓ sig. |
| neuromuscular synaptic transmission | GO:0007274 | 2 / 31 | 134× | 9.52e-5 | 3.02e-3 ✓ sig. |
| membrane depolarization | GO:0051899 | 2 / 32 | 130× | 1.02e-4 | 3.17e-3 ✓ sig. |
| intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | GO:0042771 | 2 / 33 | 126× | 1.08e-4 | 3.31e-3 ✓ sig. |
| presynaptic modulation of chemical synaptic transmission | GO:0099171 | 2 / 37 | 112× | 1.36e-4 | 3.92e-3 ✓ sig. |
| response to nicotine | GO:0035094 | 2 / 40 | 104× | 1.59e-4 | 4.42e-3 ✓ sig. |
| excitatory postsynaptic potential | GO:0060079 | 2 / 69 | 60.2× | 4.76e-4 | 9.57e-3 ✓ sig. |
Pairs within this cluster, by significance
| Disease A ⇵ | Disease B ⇵ | Similarity score ⇵ | Shared genes ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Bronchus cancer | Respiratory system cancer | 0.833 | 5 | 1.39e-19 | 2.57e-18 ✓ sig. |
| Cri-du-chat syndrome | dyskeratosis congenita, autosomal dominant 2 | 0.333 | 1 | 1.30e-4 | 3.93e-4 ✓ sig. |
| Bronchus cancer | dyskeratosis congenita, autosomal dominant 2 | 0.167 | 1 | 3.25e-4 | 7.71e-4 ✓ sig. |
| dyskeratosis congenita, autosomal dominant 2 | Respiratory system cancer | 0.167 | 1 | 3.25e-4 | 7.71e-4 ✓ sig. |
| Coumarin resistance | Large cell carcinoma | 0.200 | 1 | 3.90e-4 | 8.67e-4 ✓ sig. |
| Bronchus cancer | Cri-du-chat syndrome | 0.143 | 1 | 6.49e-4 | 1.24e-3 ✓ sig. |
| Cri-du-chat syndrome | Respiratory system cancer | 0.143 | 1 | 6.49e-4 | 1.24e-3 ✓ sig. |
| Bronchus cancer | Large cell carcinoma | 0.143 | 1 | 6.49e-4 | 1.24e-3 ✓ sig. |
| Large cell carcinoma | Respiratory system cancer | 0.143 | 1 | 6.49e-4 | 1.24e-3 ✓ sig. |
| Bronchus cancer | Coumarin resistance | 0.125 | 1 | 9.74e-4 | 1.67e-3 ✓ sig. |